Teva Pharmaceutical Industries LimitedTEVANYSE
Loading
Free Cash Flow Growth Recovery in ProgressRecovering
Percentile Rank90
3Y CAGR+51.1%
Year-over-Year Change
Year-over-year free cash flow growth rate
3Y CAGR
+51.1%/yr
vs -11.7%/yr prior
Acceleration
+62.8pp
Accelerating
Percentile
P90
Near historical high
vs 3Y Ago
3.5x
Strong expansion
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 336.05% |
| Q3 2025 | 77.86% |
| Q2 2025 | 156.47% |
| Q1 2025 | -152.02% |
| Q4 2024 | -18.17% |
| Q3 2024 | 8983.33% |
| Q2 2024 | 102.42% |
| Q1 2024 | -123.29% |
| Q4 2023 | 839.58% |
| Q3 2023 | -170.24% |
| Q2 2023 | 172.18% |
| Q1 2023 | -134.18% |
| Q4 2022 | 97.39% |
| Q3 2022 | 10625.00% |
| Q2 2022 | 98.06% |
| Q1 2022 | -167.99% |
| Q4 2021 | -20.89% |
| Q3 2021 | 264.76% |
| Q2 2021 | 118.92% |
| Q1 2021 | -458.06% |
| Q4 2020 | -5.49% |
| Q3 2020 | 15.49% |
| Q2 2020 | -19.77% |
| Q1 2020 | -57.76% |
| Q4 2019 | 168.59% |
| Q3 2019 | 146.02% |
| Q2 2019 | -2507.69% |
| Q1 2019 | -108.44% |
| Q4 2018 | -45.39% |
| Q3 2018 | 984.62% |
| Q2 2018 | -98.05% |
| Q1 2018 | 46.16% |
| Q4 2017 | 0.77% |
| Q3 2017 | 65.15% |
| Q2 2017 | 104.48% |
| Q1 2017 | -75.46% |
| Q4 2016 | -11.94% |
| Q3 2016 | 57.36% |
| Q2 2016 | -34.55% |
| Q1 2016 | -11.92% |